Edition:
United States

VBI Vaccines Inc (VBIV.OQ)

VBIV.OQ on NASDAQ Stock Exchange Capital Market

3.03USD
4:00pm EDT
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$3.03
Open
$3.02
Day's High
$3.18
Day's Low
$2.91
Volume
2,755,556
Avg. Vol
54,484
52-wk High
$5.10
52-wk Low
$2.82

Chart for

About

VBI Vaccines Inc. is a development-stage biotechnology company. The Company's principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity.... (more)

Overall

Beta: 1.55
Market Cap(Mil.): $204.85
Shares Outstanding(Mil.): 64.22
Dividend: --
Yield (%): --

Financials

  VBIV.OQ Industry Sector
P/E (TTM): -- 244.60 33.54
EPS (TTM): -0.86 -- --
ROI: -40.97 -5.33 13.09
ROE: -46.74 -6.88 15.10

BRIEF-VBI Vaccines Announces Positive Final Phase 1 Study Results Of Preventative CMV Vaccine

* VBI VACCINES ANNOUNCES POSITIVE FINAL PHASE 1 STUDY RESULTS OF PREVENTATIVE CMV VACCINE

May 10 2018

BRIEF- Vaccines Posts Q1 Loss Per Share $0.19

* VBI VACCINES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 01 2018

BRIEF-VBI Vaccines Posts Positive DSMB Review Of Recurrent Glioblastoma Study

* VBI VACCINES ANNOUNCES POSITIVE DSMB REVIEW IN PHASE 1/2A STUDY OF VBI-1901 IN RECURRENT GLIOBLASTOMA (GBM) PATIENTS

Apr 17 2018

BRIEF-Vbi Vaccines Announces Voluntary Delisting From The Toronto Stock Exchange

* VBI VACCINES ANNOUNCES VOLUNTARY DELISTING FROM THE TORONTO STOCK EXCHANGE

Mar 12 2018

BRIEF-VBI Vaccines Announces Changes To Its Board Of Directors

* VBI VACCINES INC - TOMER KARIV, CHAIRMAN AND CEO OF PONTIFAX GROUP, TO REPLACE RAN NUSSBAUM ON VBI'S BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Jan 26 2018

Earnings vs. Estimates